F4 Champions · Season 1
You're researching investors. We want to see what you're building.
Join the open accelerator where your standing changes with what you ship. Enrollment closes August 2.
F4 Champions · Season 1
You're researching investors. We want to see what you're building.
Join the open accelerator where your standing changes with what you ship. Enrollment closes August 2.
7 VC firms investing in insurance and biotech & life sciences at the Series B stage.
F4 Fund tracks 7 VC firms that actively invest in insurance + biotech & life sciences at the Series B stage, with check sizes ranging from $500K – $500M (median: $30.3M – $30.3M). As of July 2026, and 100% lead or co-lead rounds. Rankings are based on F4's proprietary analysis of 1,521+ researched VC firms, scored by data completeness, portfolio depth, investment recency, and stage alignment.
| # | Firm | Check Size | Portfolio | Leads? | Activity | Decision | Intro |
|---|---|---|---|---|---|---|---|
| 1 | ▶ Oak HC/FT Oak HC/FT partners with founders driving structural change in healthcare and financial services. They believe the most durable companies in the AI era will combine AI velocity with genuine understanding of how these industries work — including their regulatory, distribution, and trust dynamics. Interested in horizontal platforms that can penetrate and win in these complex, regulated sectors. Stamford | $1M – $100M | 34 | Leads | Active | ~1 mo | Open |
| 2 | ▶ Spark Capital Spark Capital backs transformative products built by creators with genuine vision and technical depth. We believe that the best way to evaluate a founding team is not through credentials or market analysis, but by experiencing their product firsthand. Product comes first, and everything else follows. | $500K – $60M | 65 | Both | Active | ~2 wks | Open |
| 3 | ▶ Mundi Ventures Mundi backs bold, purpose-driven founders building technology companies at the intersection of deep tech and critical global challenges. Core thesis: Europe has world-class talent and ecosystem but suffers from a scale-up funding gap at growth stages. Kembara fund (€750M) bridges this by providing Series B/C growth capital to European deep tech and climate champions. Madrid | $1M – $40M | 54 | Leads | Active | ~2 mo | Open |
| 4 | ▶ Moderne Ventures Generalist investors with vertical expertise. We invest in bold, broad, multi-vertical technology companies applicable to multi-trillion dollar industries (real estate, finance, insurance, sustainability). Our distinctive Moderne Passport program creates value by connecting 1,500+ corporate executives with portfolio companies, generating customers, strategic partnerships, and operational guidance. Chicago | $2M – $25M | 27 | Leads | Active | ~2 wks | Req'd |
| 5 | ▶ Caffeinated Capital Support founders pursuing their life's work with an alternative to the hype cycle: the luxury of long-term thinking. We support founders building category-defining companies across all sectors that will last for lifetimes. San Francisco | $1M – $5M | 18 | Leads | Active | N/A | N/A |
| 6 | ▶ Cathay Innovation Startups positioned as transformation partners with Fortune 500 corporates create the most impactful solutions. We believe the next generation of market leaders will emerge through collaborative innovation between startups and incumbent enterprises, supported by global expertise and capital. Paris | $5M – $100M | 16 | Both | Active | ~1 mo | Req'd |
| 7 | ▶ Gigafund Back the world's most ambitious and transformative entrepreneurs capable of building world-defining companies over 20+ years. Invest in founders with independent thought and first-principles vision to solve humanity's biggest problems across all sectors and geographies. Austin | $1M – $500M | 18 | Leads | Active | 3+ mo | Open |
What other stages do these firms also invest in?
Investors on this page also frequently invest in these sectors
What other sectors do these firms also invest in?
F4 Fund tracks 7 VC firms that actively invest in insurance + biotech & life sciences at the Series B stage. These firms are ranked using a composite score that weighs data completeness (30%), portfolio depth (30%), investment recency (25%), and stage alignment (15%).
Based on F4's analysis, the median check size for series b insurance + biotech & life sciences investors is $30.3M – $30.3M, with a full range from $500K – $500M. The distribution breaks down as: 1 firms in the $2M-$5M range, 6 firms in the $10M+ range.
Among the 7 firms tracked, 100% lead or co-lead rounds. Founders seeking a lead investor should filter for firms marked "Leads" or "Both" in the rankings table above. Lead investors typically set deal terms and anchor the round.
The best series b insurance + biotech & life sciences investors combine domain expertise with an active portfolio in the space. Among these firms, 33% prefer warm introductions, and the average firm has 33 portfolio companies. Look for firms whose check size matches your raise, whose stage preference aligns with yours, and who have a track record of supporting companies in your sector through multiple growth phases.
Firm profiles are continuously updated through F4's research pipeline, which combines LLM-powered web research, portfolio analysis, and transcript extraction. The ranking data refreshes every 12 hours. Editorial analysis is reviewed weekly. Individual firm profiles are re-researched on a 30-day cycle or when new information surfaces.